Home FDA labels a5b4a5de-7bb4-4685-e053-2995a90ad76e FDA label a5b4a5de-7bb4-4685-e053-2995a90ad76e openFDA label record# This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)
SPL set ID 71c60c3f-a9ab-abab-e053-2a95a90a8689
SPL ID a5b4a5de-7bb4-4685-e053-2995a90ad76e
Version 2
Effective date 2020-05-15
Source export date 2026-09-28
Source partition 10
Source file https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
Source object key raw/openfda/drug-label/2026-09-28/4bbc9760f647649b787710953d978bd6419e899ba8b90f32c3d972aae43947f8/drug-label-0010-of-0014.json.zip
Source manifest SHA-256 cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run 20260929T050834Z
Imported at 2026-09-29 06:10:37 Harmonized identifier links# Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
Harmonized identifiers page 1 of 1 · 2 matching rows.
Adverse reactions cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions sections page 1 of 1 · 2 matching rows.
adverse reactions ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Perioral dermatitis Itching Allergic contact dermatitis Irritation Maceration of the skin Dryness Secondary infection Folliculitis Skin atrophy Hypertrichosis Striae Acneiform eruptions Miliaria Hypopigmentation
adverse reactions table <table width="60%"> <col align="left" valign="top" width="45%"/> <col align="left" valign="top" width="55%"/> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Burning</td> <td styleCode="Rrule">Perioral dermatitis</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Itching</td> <td styleCode="Rrule">Allergic contact dermatitis</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Irritation</td> <td styleCode="Rrule">Maceration of the skin</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Dryness</td> <td styleCode="Rrule">Secondary infection</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Folliculitis</td> <td styleCode="Rrule">Skin atrophy</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Hypertrichosis</td> <td styleCode="Rrule">Striae</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Acneiform eruptions</td> <td styleCode="Rrule">Miliaria</td> </tr> <tr> <td styleCode="Lrule Rrule">Hypopigmentation</td> <td styleCode="Rrule"/> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.